Alkem Laboratories Limited

BSE: ALKEM539523ISIN INE540L01014

Healthcare
Pharmaceuticals
BSE 200

BSE listing

Share price

₹5,501.60+161.60 (+3.03%)

as of 18 Sep 2026

52W high: ₹5,933.00
52W low: ₹5,052.05
Off 52W high: -7.27%
1M return: +2.25%
3M return: +2.36%
6M return: +4.64%
1Y return: +0.42%
20D avg volume: 16,715
50 DMA: ₹5,454.62
200 DMA: ₹5,500.79

Key ratios Consolidated

Market cap: ₹65,780 Cr
Current price: ₹5,501.60
52W high / low: ₹5,933.00 / ₹5,052.05
Face value: ₹2.00
P/E: 29.84
P/B: —
EPS (TTM): ₹184.35
Book value / share: —
ROE: —
ROCE: 18.80%
Operating margin: —
Net margin: —
Debt / equity: 0.11
Net debt: ₹1,376 Cr
Interest cover: 18.86
Dividend yield: 0.96%
Dividend / share (TTM): ₹53.00
Payout: 28.75%
Cash conversion cycle: 100.9 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	3,740	3,603	3,737	4,001	3,371	3,144	3,374	3,415	3,032	2,936	3,324	3,440
	152.75	200.07	143.10	103.69	136.49	145.96	92.99	134.48	120.31	88.17	93.64	63.19
	3,121	3,246	3,046	3,209	2,750	2,893	2,736	2,769	2,533	2,644	2,711	2,798
	910.02	894.94	937.77	905.57	827.11	777.03	924.01	902.17	837.16	798.76	838.54	824.71
	365.99	497.77	327.96	471.57	397.20	379.96	397.48	353.92	382.66	380.70	460.81	431.89
	808.90	712.10	721.51	710.25	693.25	616.35	624.81	610.49	602.27	505.83	572.15	555.38
	46.62	53.88	42.10	35.02	29.78	28.42	36.03	28.14	29.11	26.86	25.46	30.32
	100.19	105.76	95.01	93.61	87.68	112.49	85.28	78.91	80.48	83.43	69.56	73.90
	963.93	1,126	914.60	968.94	767.68	856.83	785.75	846.65	744.96	920.61	739.59	810.99
	771.99	557.82	833.99	895.83	758.08	396.34	731.07	780.26	619.36	379.86	706.21	705.70
	0.00	-134.97	-52.79	0.00	12.93	0.00	0.00	0.00	0.00	-12.52	-51.31	-57.66
	771.99	422.85	781.20	895.83	771.01	396.34	731.07	780.26	619.36	367.34	654.90	648.04
	250.50	171.17	127.67	116.23	102.69	73.33	90.28	78.30	69.12	62.86	50.62	33.15
	520.98	251.11	653.03	779.11	667.91	322.39	640.79	701.96	550.24	304.48	604.28	614.89
	43.49	19.77	53.19	63.99	55.56	25.57	52.34	57.60	45.60	24.55	49.76	51.90
Key metrics
	918.80	582.49	918.31	1,024	888.47	537.25	852.38	887.31	728.95	477.63	749.92	752.26
	24.60%	16.20%	24.60%	25.60%	26.40%	17.10%	25.30%	26.00%	24.00%	16.30%	22.60%	21.90%
	13.90%	7.00%	17.50%	19.50%	19.80%	10.30%	19.00%	20.60%	18.10%	10.40%	18.20%	17.90%
	—	3.00%	—	6.00%	—	3.10%	—	—	—	—	—	—
	10.90%	14.60%	10.70%	17.20%	11.20%	7.10%	1.50%	-0.70%	—	—	—	—
	-22.00%	-22.10%	1.90%	11.00%	21.40%	5.90%	6.00%	14.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	15,081	14,712	12,965	12,668	11,599	10,634	8,865	8,344	7,357	6,431	5,852
	599.61	583.35	493.74	310.84	216.08	162.65	233.21	104.22	87.70	95.95	112.01
	12,621	12,250	10,931	10,834	10,408	8,938	7,256	7,189	6,490	5,601	5,000
	3,648	3,565	3,440	3,295	3,057	3,226	2,395	2,132	1,811	1,567	1,449
	1,663	1,694	1,514	1,629	1,388	1,490	1,438	1,443	1,130	1,036	1,062
	2,953	2,837	2,454	2,201	2,131	1,963	1,621	1,505	1,362	1,192	1,004
	177.62	160.78	121.70	112.41	107.36	52.37	58.92	65.06	54.63	55.33	45.16
	394.57	382.06	357.16	299.30	310.42	303.96	274.58	252.76	193.18	—	101.17
	3,973	3,777	3,234	3,284	2,952	2,438	1,803	2,021	1,935	1,698	1,628
	3,060	3,046	2,527	2,145	1,408	1,859	1,842	1,260	954.66	925.98	964.63
	-187.76	-174.83	0.00	-121.49	-102.98	-14.96	0.00	0.00	0.00	0.00	0.00
	2,872	2,871	2,527	2,023	1,305	1,844	1,842	1,260	954.66	925.98	964.63
	665.57	517.76	311.03	211.67	297.96	163.96	224.33	110.48	181.02	287.56	59.96
	2,204	2,351	2,215	1,811	1,007	1,680	1,618	1,149	773.64	638.42	904.67
	180.44	192.51	181.11	150.19	82.31	137.63	132.57	94.26	63.61	—	—
Key metrics
	3,444	3,414	3,006	2,435	1,723	2,201	2,176	1,578	1,202	981.31	1,111
	22.84%	23.20%	23.20%	19.20%	14.90%	20.70%	24.50%	18.90%	16.30%	15.30%	19.00%
	14.62%	16.00%	17.10%	14.30%	8.70%	15.80%	18.20%	13.80%	10.50%	9.90%	15.50%
	—	18.80%	19.30%	—	—	—	—	—	—	—	—
	—	13.50%	2.30%	9.20%	9.10%	20.00%	6.20%	13.40%	14.40%	9.90%	—
	—	6.10%	22.30%	79.90%	-40.10%	3.90%	40.80%	48.60%	21.20%	-29.40%	—
	—	1,346	1,237	—	—	—	—	—	—	—	—
	—	0.83	0.86	—	—	—	—	—	—	—	—
	—	0.11	0.09	—	—	—	—	—	—	—	—
	—	1,376	758.65	—	—	—	—	—	—	—	—
	—	100.9	99.9	—	—	—	—	—	—	—	—
Balance sheet
	—	20,873	17,691	—	—	—	—	—	—	—	—
	—	12,211	10,811	—	—	—	—	—	—	—	—
	—	247.91	304.14	—	—	—	—	—	—	—	—
	—	2,979	2,466	—	—	—	—	—	—	—	—
	—	3,333	2,922	—	—	—	—	—	—	—	—
	—	898.83	832.67	—	—	—	—	—	—	—	—
	—	2,695	2,064	—	—	—	—	—	—	—	—
	—	2,244	1,839	—	—	—	—	—	—	—	—
	—	4,783	3,959	—	—	—	—	—	—	—	—
	—	1,624	1,063	—	—	—	—	—	—	—	—
	—	1,131	751.88	—	—	—	—	—	—	—	—
	—	492.45	310.91	—	—	—	—	—	—	—	—
	—	14,349	12,434	—	—	—	—	—	—	—	—
Cash flow
	—	1,963	1,913	—	—	—	—	—	—	—	—
	—	-1,667	-1,299	—	—	—	—	—	—	—	—
	—	-503.40	-810.99	—	—	—	—	—	—	—	—
	—	617.26	675.62	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,668	2,258	2,491	2,542	2,372	2,045	2,287	2,872	2,500	2,365	2,495	2,635
	136.62	205.69	131.53	101.37	116.58	111.59	169.18	120.19	106.10	83.79	95.66	61.84
	2,006	2,009	1,878	1,843	1,823	1,857	1,718	2,224	1,965	2,048	2,005	2,058
	672.88	658.86	587.51	567.63	615.33	451.41	693.13	732.29	761.23	652.71	700.73	707.12
	146.66	107.50	113.10	122.84	83.51	85.24	120.90	315.40	207.36	269.96	331.18	282.39
	547.47	466.86	485.58	460.85	469.74	401.63	418.48	429.76	425.90	343.41	407.63	395.18
	17.52	16.24	15.51	12.75	12.79	16.91	21.00	17.57	21.44	20.68	21.11	18.70
	57.22	78.17	60.91	58.59	58.89	91.64	67.61	62.59	64.35	69.10	58.12	59.02
	627.67	747.87	600.20	622.63	575.18	622.73	484.64	627.51	570.64	683.10	513.20	584.64
	798.42	455.30	744.32	800.71	665.38	299.83	738.40	767.67	640.94	401.53	585.69	638.72
	0.00	-119.21	-38.17	0.00	14.29	0.00	—	—	—	-12.52	-51.31	—
	798.42	336.09	706.15	800.71	679.67	299.83	738.40	767.67	640.94	389.01	534.38	638.72
	228.44	119.03	84.01	77.05	57.41	73.95	62.17	70.09	57.69	64.04	30.15	7.79
	569.98	217.06	622.14	786.73	656.16	276.94	723.12	697.58	583.25	324.97	504.23	646.51
	47.67	18.16	52.03	65.80	54.88	23.17	56.56	58.34	48.78	27.18	42.17	54.07
Key metrics
	873.16	430.50	782.57	872.05	751.35	408.38	827.01	847.83	726.73	478.79	613.61	716.44
	32.70%	19.10%	31.40%	34.30%	31.70%	20.00%	36.20%	29.50%	29.10%	20.20%	24.60%	27.20%
	21.40%	9.60%	25.00%	30.90%	27.70%	13.50%	31.60%	24.30%	23.30%	13.70%	20.20%	24.50%
	—	2.40%	—	5.60%	—	2.40%	—	—	—	—	—	—
	12.50%	10.40%	8.90%	-11.50%	-5.10%	-13.50%	-8.30%	9.00%	—	—	—	—
	-13.10%	-21.60%	-14.00%	12.80%	12.50%	-14.80%	43.40%	7.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	9,959	9,664	8,813	9,748	9,055	8,830	7,220	6,677	5,714	5,300	4,668
	575.21	555.17	507.06	305.99	266.29	199.89	190.01	95.98	67.58	81.66	116.60
	7,736	7,553	7,017	8,109	7,994	7,276	5,513	5,435	4,838	4,448	3,891
	2,487	2,429	2,396	2,750	2,630	2,850	2,047	1,800	1,497	1,328	1,232
	490.10	426.95	389.61	1,129	943.13	1,077	919.79	784.38	688.09	838.95	775.04
	1,961	1,883	1,631	1,560	1,516	1,434	1,159	1,067	960.09	861.63	722.25
	62.02	57.29	76.11	81.91	86.40	37.90	42.93	38.71	28.26	32.37	23.68
	254.89	256.56	283.61	244.35	229.85	218.98	198.93	186.84	141.07	107.65	76.48
	2,598	2,546	2,184	2,415	2,331	2,019	1,447	1,592	1,436	1,371	1,273
	2,799	2,666	2,304	1,945	1,327	1,753	1,897	1,338	943.96	934.29	894.43
	-157.38	-143.09	0.00	-63.83	—	—	-12.78	—	—	—	—
	2,641	2,523	2,304	1,881	1,327	1,753	1,884	1,338	943.96	934.29	894.43
	508.53	337.50	213.82	133.88	192.52	212.12	199.22	73.66	144.12	218.45	11.27
	2,196	2,282	2,281	1,747	1,134	1,541	1,685	1,264	799.84	715.84	883.16
	183.66	190.87	190.77	146.13	94.88	128.90	140.93	105.75	66.90	—	—
Key metrics
	2,958	2,836	2,663	2,207	1,643	2,010	2,126	1,564	1,113	1,074	994.59
	29.70%	29.40%	30.20%	22.60%	18.10%	22.80%	29.40%	23.40%	19.50%	20.30%	21.30%
	22.05%	23.60%	25.90%	17.90%	12.50%	17.50%	23.30%	18.90%	14.00%	13.50%	18.90%
	—	17.80%	18.20%	—	—	—	—	—	—	—	—
	—	9.60%	-9.60%	7.70%	2.50%	22.30%	8.10%	16.90%	7.80%	13.50%	—
	—	0.10%	30.50%	54.00%	-26.40%	-8.50%	33.30%	58.10%	11.70%	-18.90%	—
	—	1,692	1,963	—	—	—	—	—	—	—	—
	—	0.86	0.96	—	—	—	—	—	—	—	—
	—	0.04	0.03	—	—	—	—	—	—	—	—
	—	473.79	296.32	—	—	—	—	—	—	—	—
	—	65.0	67.1	—	—	—	—	—	—	—	—
Balance sheet
	—	17,261	15,596	—	—	—	—	—	—	—	—
	—	7,830	7,354	—	—	—	—	—	—	—	—
	—	65.45	74.92	—	—	—	—	—	—	—	—
	—	1,567	1,560	—	—	—	—	—	—	—	—
	—	1,632	1,523	—	—	—	—	—	—	—	—
	—	690.77	633.65	—	—	—	—	—	—	—	—
	—	1,422	1,482	—	—	—	—	—	—	—	—
	—	1,476	1,464	—	—	—	—	—	—	—	—
	—	2,747	2,543	—	—	—	—	—	—	—	—
	—	539.24	371.24	—	—	—	—	—	—	—	—
	—	539.24	371.24	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	13,999	12,322	—	—	—	—	—	—	—	—
Cash flow
	—	1,969	2,189	—	—	—	—	—	—	—	—
	—	-1,461	-1,007	—	—	—	—	—	—	—	—
	—	-672.82	-1,037	—	—	—	—	—	—	—	—
	—	277.27	226.20	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +2.19%
Sales CAGR 5Y: +6.01%
Sales CAGR 10Y: —
Profit CAGR 3Y: +26.23%
Profit CAGR 5Y: +6.25%
Profit CAGR 10Y: —
Sales YoY (TTM): +4.01%
Profit YoY (TTM): -6.71%

Consolidated

Sales CAGR 3Y: +8.25%
Sales CAGR 5Y: +10.66%
Sales CAGR 10Y: —
Profit CAGR 3Y: +32.67%
Profit CAGR 5Y: +7.76%
Profit CAGR 10Y: —
Sales YoY (TTM): +13.36%
Profit YoY (TTM): -5.52%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Filings & corporate actions

Recent announcements

Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial - onset seizures in adult patients.16 Sep 2026 · Company Update / Press Release / Media Release
Please find attached herewith intimation for appointment of Dr. Shubhadeep Sinha as Senior Management Personnel of the Company.15 Sep 2026 · Company Update / Change in Management
Alkem Laboratories Limited launches Renocia ExoTM, India''s first patented Ginsenoside Exosome - based hair growth serum8 Sep 2026 · Company Update / Press Release / Media Release
Please find attached herewith Scrutinizer Report for 52nd Annual General Meeting of the Company.27 Aug 2026 · AGM/EGM / AGM
Please find attached herewith Outcome of the 52nd Annual General Meeting of the Company and disclosure of voting results thereat.27 Aug 2026 · AGM/EGM / AGM
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund26 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Please find attached herewith Q1 FY27- Earnings Call Transcript.20 Aug 2026 · Company Update / Earnings Call Transcript
Please find attached herewith Q1 FY27- Earnings Call Transcript.20 Aug 2026 · Company Update / Earnings Call Transcript
Please find attached herewith Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer''s Report on e-voting.17 Aug 2026 · AGM/EGM / Court Convened Meeting
Please find attached herewith intimation for a copy of newspaper publication15 Aug 2026 · Company Update / Newspaper Publication
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q1FY27 Earnings Conference Call'' is available ....14 Aug 2026 · Company Update / Analyst / Investor Meet
The Financials Results of the Company for the quarter ended 30th June, 2026 having been communicated to the Stock Exchanges today ie 14th Aug the trading window shall open on 17th Aug, 2026.14 Aug 2026 · Insider Trading / SAST / Closure of Trading Window
Pl find enclosed press release and analyst presentation on Q1FY27 earnings and business updates of the Company14 Aug 2026 · Company Update / Investor Presentation
Pl find attached herewith intimation under Reg 3014 Aug 2026 · Company Update / General
Pl find enclosed unaudited financial results along with LRR for quarter ended 30th June, 202614 Aug 2026 · Result / Financial Results
Please find enclosed herewith the outcome of Board meeting dated 14th Aug, 2026. The meeting of the Board of Directors of the Company commenced at 11 am and concluded at 13.40 pm. Kindly take the same14 Aug 2026 · Board Meeting / Outcome of Board Meeting
Please find attached herewith intimation about update on US FDA inspection at Company''s Manufacturing Facility Located at Amaliya, Daman.6 Aug 2026 · Company Update / General
Please find attached herewith regarding Appointment of Senior Management Personnel.3 Aug 2026 · Company Update / Change in Management
Please find attached herewith Disclosure under Regulation 30 of the SEBI (LODR) Regulation 2015.30 Jul 2026 · Company Update / General
Please find attached herewith a copy Newspaper Publication.30 Jul 2026 · Company Update / Newspaper Publication
Please find attached herewith the Notice of AGM alongwith the Annual Report for the FY 2025-2026.29 Jul 2026 · AGM/EGM / AGM
Please find attached herewith the Business Responsibility and Sustainability Report for the financial year ended 31st March, 2026.29 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Please find enclosed herewith the Notice of the 52nd Annual General Meeting of the Company scheduled to be held on Thursday, 27th August, 2026 at 11.00 a.m. through Video Conferencing (VC)/ ....29 Jul 2026 · Others / Reg. 34 (1) Annual Report
Please find attached herewith intimation for Analyst / Investor Meet.27 Jul 2026 · Company Update / Analyst / Investor Meet
Please find attached herewith Intimation regarding Resignation of Senior Management Personnel.23 Jul 2026 · Company Update / Change in Management
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Please find attached herewith ....21 Jul 2026 · Board Meeting / Board Meeting
Please Find Attached herewith intimation regarding update on Acquisition.17 Jul 2026 · Company Update / Acquisition
Please find attached herewith Newspaper Publication.16 Jul 2026 · Company Update / Newspaper Publication
Please find attached herewith Disclosure under Regulation 30 of the SEBI LODR Regulations, 2015.16 Jul 2026 · Company Update / Acquisition
Notice convening the meeting of the equity shareholders of the Company15 Jul 2026 · AGM/EGM / Court Convened Meeting
Please find attached herewith the copy of Newspaper Publication.2 Jul 2026 · Company Update / Newspaper Publication
Please Find Attached herewith disclosure in respect of order passed by the Statutory Authority.1 Jul 2026 · Company Update / General
Please find attached herewith Copy of Newspaper Publication.30 Jun 2026 · Company Update / Newspaper Publication
Please find attached herewith Analyst / Investor Meet - Intimation.29 Jun 2026 · Company Update / Analyst / Investor Meet
Please find attached herewith Analyst / Investor Meet - Intimation.29 Jun 2026 · Company Update / Analyst / Investor Meet
Please find enclosed herewith disclosure under Regulation 30 of SEBI LODR Regulations, 2015 - Updates on Acquisition29 Jun 2026 · Company Update / Acquisition
Please Find Attached herewith intimation regarding Closure of Trading Window.24 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Please find attached herewith Analyst / Investor Meet - Intimation.15 Jun 2026 · Company Update / Analyst / Investor Meet
Please find attached herewith Analyst / Investor Meet - Intimation.10 Jun 2026 · Company Update / Analyst / Investor Meet
Samprada & Nanhamati Singh Family Trust has submitted a letter to Exchange on amendment to trust deed under Regulation 11(5) of The Securities and Exchange Board of India (Substantial ....3 Jun 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 10.0000	7 Aug 2026	7 Aug 2026	—
Interim Dividend - Rs. - 43.0000	20 Feb 2026	20 Feb 2026	—
Final Dividend - Rs. - 8.0000	8 Aug 2025	8 Aug 2025	—
Interim Dividend - Rs. - 37.0000	14 Feb 2025	14 Feb 2025	—
Final Dividend - Rs. - 5.0000	9 Aug 2024	10 Aug 2024	—

Board meetings

14 Aug 2026 Board Meeting - Financial Results